What 8 Analyst Ratings Have To Say About Genmab
What 8 Analyst Ratings Have To Say About Genmab
关于genmab，8位分析师的评级是怎样的？
The...8 analysts have expressed a variety of opinions on Genmab (NASDAQ:GMAB) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在过去的一个季度中，8位分析师对Genmab（纳斯达克股票代码：GMAB）表达了各种观点，从看涨到看跌，提出了各种各样的观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts have set 12-month price targets for Genmab, revealing an average target of $50.0, a high estimate of $53.00, and a low estimate of $47.00. This upward trend is apparent, with the current average reflecting a 1.01% increase from the previous average price target of $49.50.
分析师已经为Genmab设定了12个月的目标股价，显示平均目标股价为50.0美元，最高估计为53.00美元，低估值为47.00美元。这种上升趋势显而易见，当前的平均价格较之前的平均目标价49.50美元上涨了1.01％。
Exploring Analyst Ratings: An In-Depth Overview
探索分析师评级：深入概述
The...
通...
登录免费看全文
登录/注册